array(40) {
  [0]=>
  string(4) "5131"
  ["article_id"]=>
  string(4) "5131"
  [1]=>
  string(123) "MacroGenics announces initiation of phase 2/3 MAHOGANY study of margetuximab in gastric or gastroesophageal junction cancer"
  ["article_title"]=>
  string(123) "MacroGenics announces initiation of phase 2/3 MAHOGANY study of margetuximab in gastric or gastroesophageal junction cancer"
  [2]=>
  string(154) "“The MAHOGANY study for patients with gastric or gastroesophageal junction cancer is designed to support registration of margetuximab and is a part "
  ["short_description"]=>
  string(154) "“The MAHOGANY study for patients with gastric or gastroesophageal junction cancer is designed to support registration of margetuximab and is a part "
  [3]=>
  string(712) "
“The MAHOGANY study for patients with gastric or gastroesophageal junction cancer is designed to support registration of margetuximab and is a part of our strategy to advance margetuximab 
&#nl
The post MacroGenics announces initiation of phase 2/3 MAHOGANY study of margetuximab in gastric or gastroesophageal junction cancer appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(712) "
“The MAHOGANY study for patients with gastric or gastroesophageal junction cancer is designed to support registration of margetuximab and is a part of our strategy to advance margetuximab 
&#nl
The post MacroGenics announces initiation of phase 2/3 MAHOGANY study of margetuximab in gastric or gastroesophageal junction cancer appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(176) "https://www.pharmaceutical-business-review.com/news/macrogenics-announces-initiation-of-phase-2-3-mahogany-study-of-margetuximab-in-gastric-or-gastroesophageal-junction-cancer/"
  ["blog_url"]=>
  string(176) "https://www.pharmaceutical-business-review.com/news/macrogenics-announces-initiation-of-phase-2-3-mahogany-study-of-margetuximab-in-gastric-or-gastroesophageal-junction-cancer/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-10-31 15:49:39"
  ["create_at"]=>
  string(19) "2019-10-31 15:49:39"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "5132"
  ["article_id"]=>
  string(4) "5132"
  [1]=>
  string(120) "LIPAC Oncology announces successful completion of phase 1 bladder cancer clinical study and initiation of phase 2A study"
  ["article_title"]=>
  string(120) "LIPAC Oncology announces successful completion of phase 1 bladder cancer clinical study and initiation of phase 2A study"
  [2]=>
  string(150) "Phase 1 study results showed escalating doses of TBC-1002 to be well tolerated with no dose limiting toxicity and no irritative voiding (cystitis) sym"
  ["short_description"]=>
  string(150) "Phase 1 study results showed escalating doses of TBC-1002 to be well tolerated with no dose limiting toxicity and no irritative voiding (cystitis) sym"
  [3]=>
  string(693) "
Phase 1 study results showed escalating doses of TBC-1002 to be well tolerated with no dose limiting toxicity and no irritative voiding (cystitis) symptoms. No systemic exposure or 
&#nl
The post LIPAC Oncology announces successful completion of phase 1 bladder cancer clinical study and initiation of phase 2A study appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(693) "
Phase 1 study results showed escalating doses of TBC-1002 to be well tolerated with no dose limiting toxicity and no irritative voiding (cystitis) symptoms. No systemic exposure or 
&#nl
The post LIPAC Oncology announces successful completion of phase 1 bladder cancer clinical study and initiation of phase 2A study appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(173) "https://www.pharmaceutical-business-review.com/news/lipac-oncology-announces-successful-completion-of-phase-1-bladder-cancer-clinical-study-and-initiation-of-phase-2a-study/"
  ["blog_url"]=>
  string(173) "https://www.pharmaceutical-business-review.com/news/lipac-oncology-announces-successful-completion-of-phase-1-bladder-cancer-clinical-study-and-initiation-of-phase-2a-study/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-10-31 15:49:39"
  ["create_at"]=>
  string(19) "2019-10-31 15:49:39"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "5340"
  ["article_id"]=>
  string(4) "5340"
  [1]=>
  string(159) "TSI Reports Enrollment of First 10 Patients in its Phase 2 Ischemic Stroke Clinical Trial and Completion of its Phase 2 Study Protocol in Myocardial Infarction"
  ["article_title"]=>
  string(159) "TSI Reports Enrollment of First 10 Patients in its Phase 2 Ischemic Stroke Clinical Trial and Completion of its Phase 2 Study Protocol in Myocardial Infarction"
  [2]=>
  string(150) "Studies Aim to Confirm Safety and Efficacy of Novel Bio-inspired Clot-dissolving TherapyCambridge, Mass., October 30, 2019 -- Thrombolytic Science, LL"
  ["short_description"]=>
  string(150) "Studies Aim to Confirm Safety and Efficacy of Novel Bio-inspired Clot-dissolving TherapyCambridge, Mass., October 30, 2019 -- Thrombolytic Science, LL"
  [3]=>
  string(575) "Studies Aim to Confirm Safety and Efficacy of Novel Bio-inspired Clot-dissolving TherapyCambridge, Mass., October 30, 2019 -- Thrombolytic Science, LLC (TSI) today announced progress with 10 patients enrolled in its prospective, randomized, multicenter Phase 2 clinical trial, designed to confirm the safety and efficacy of the sequential dual-treatment regimen of low-dose tissue plasminogen activator (tPA) and HisproUK (TSI’s mutant prourokinase [proUK]) in 200 ischemic stroke patients. The clinical trial is led by Prof. Diederik Dippel,...&#nl&#nlSource: RealWire"
  ["description"]=>
  string(575) "Studies Aim to Confirm Safety and Efficacy of Novel Bio-inspired Clot-dissolving TherapyCambridge, Mass., October 30, 2019 -- Thrombolytic Science, LLC (TSI) today announced progress with 10 patients enrolled in its prospective, randomized, multicenter Phase 2 clinical trial, designed to confirm the safety and efficacy of the sequential dual-treatment regimen of low-dose tissue plasminogen activator (tPA) and HisproUK (TSI’s mutant prourokinase [proUK]) in 200 ischemic stroke patients. The clinical trial is led by Prof. Diederik Dippel,...&#nl&#nlSource: RealWire"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "64"
  ["rss_id"]=>
  string(2) "64"
  [14]=>
  string(99) "http://www.realwire.com/releases/TSI-Reports-Enrollment-of-First-Patients-in-Phase-2-Clinical-Trial"
  ["blog_url"]=>
  string(99) "http://www.realwire.com/releases/TSI-Reports-Enrollment-of-First-Patients-in-Phase-2-Clinical-Trial"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-10-31 15:50:33"
  ["create_at"]=>
  string(19) "2019-10-31 15:50:33"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "5341"
  ["article_id"]=>
  string(4) "5341"
  [1]=>
  string(63) "BioMed X completes Alzheimer’s disease research project "
  ["article_title"]=>
  string(63) "BioMed X completes Alzheimer’s disease research project "
  [2]=>
  string(150) "Heidelberg, Germany, October 28th, 2019 – BioMed X announced today the successful completion of their first research collaboration project with "
  ["short_description"]=>
  string(150) "Heidelberg, Germany, October 28th, 2019 – BioMed X announced today the successful completion of their first research collaboration project with "
  [3]=>
  string(586) "Heidelberg, Germany, October 28th, 2019 – BioMed X announced today the successful completion of their first research collaboration project with AbbVie in the field of tau-mediated neurodegeneration in Alzheimer’s disease. BioMed X received a milestone payment and the results of the project were transferred to AbbVie. The BioMed X team successfully developed research tools to assess disease-associated post-translational modification signatures of the tau protein in the brains and cerebrospinal fluids of sporadic Alzheimer’s patients and...&#nl&#nlSource: RealWire"
  ["description"]=>
  string(586) "Heidelberg, Germany, October 28th, 2019 – BioMed X announced today the successful completion of their first research collaboration project with AbbVie in the field of tau-mediated neurodegeneration in Alzheimer’s disease. BioMed X received a milestone payment and the results of the project were transferred to AbbVie. The BioMed X team successfully developed research tools to assess disease-associated post-translational modification signatures of the tau protein in the brains and cerebrospinal fluids of sporadic Alzheimer’s patients and...&#nl&#nlSource: RealWire"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "64"
  ["rss_id"]=>
  string(2) "64"
  [14]=>
  string(87) "http://www.realwire.com/releases/BioMed-X-completes-Alzheimers-disease-research-project"
  ["blog_url"]=>
  string(87) "http://www.realwire.com/releases/BioMed-X-completes-Alzheimers-disease-research-project"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-10-31 15:50:33"
  ["create_at"]=>
  string(19) "2019-10-31 15:50:33"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "5342"
  ["article_id"]=>
  string(4) "5342"
  [1]=>
  string(77) "G&L Scientific Inc announces the opening of new offices in Basel, Switzerland"
  ["article_title"]=>
  string(77) "G&L Scientific Inc announces the opening of new offices in Basel, Switzerland"
  [2]=>
  string(150) "Basel, October 2nd, 2019 G&L Scientific Inc., a market-leading, multinational, scientific consultancy with over 25 years at the forefront of Regul"
  ["short_description"]=>
  string(150) "Basel, October 2nd, 2019 G&L Scientific Inc., a market-leading, multinational, scientific consultancy with over 25 years at the forefront of Regul"
  [3]=>
  string(552) "Basel, October 2nd, 2019 G&L Scientific Inc., a market-leading, multinational, scientific consultancy with over 25 years at the forefront of Regulatory Affairs and Quality Assurance, has announced the opening of new offices in Basel, Switzerland. The company cites increased demand from clients in Continental Europe as the driver for this latest expansion.“The opening of these additional offices in Switzerland reaffirms G&L’s commitment to both new and existing clients in Europe — an area of key...&#nl&#nlSource: RealWire"
  ["description"]=>
  string(552) "Basel, October 2nd, 2019 G&L Scientific Inc., a market-leading, multinational, scientific consultancy with over 25 years at the forefront of Regulatory Affairs and Quality Assurance, has announced the opening of new offices in Basel, Switzerland. The company cites increased demand from clients in Continental Europe as the driver for this latest expansion.“The opening of these additional offices in Switzerland reaffirms G&L’s commitment to both new and existing clients in Europe — an area of key...&#nl&#nlSource: RealWire"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "64"
  ["rss_id"]=>
  string(2) "64"
  [14]=>
  string(101) "http://www.realwire.com/releases/G-and-L-Scientific-Inc-announces-the-opening-of-new-offices-in-Basel"
  ["blog_url"]=>
  string(101) "http://www.realwire.com/releases/G-and-L-Scientific-Inc-announces-the-opening-of-new-offices-in-Basel"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-10-31 15:50:33"
  ["create_at"]=>
  string(19) "2019-10-31 15:50:33"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "5343"
  ["article_id"]=>
  string(4) "5343"
  [1]=>
  string(44) "PSI Services (PSI) acquires Cubiks Group Ltd"
  ["article_title"]=>
  string(44) "PSI Services (PSI) acquires Cubiks Group Ltd"
  [2]=>
  string(150) "London, UK –28 October – PSI Services (PSI), a global workforce solutions provider with over 70 years’ experience in assessment and "
  ["short_description"]=>
  string(150) "London, UK –28 October – PSI Services (PSI), a global workforce solutions provider with over 70 years’ experience in assessment and "
  [3]=>
  string(574) "London, UK –28 October – PSI Services (PSI), a global workforce solutions provider with over 70 years’ experience in assessment and talent management, today announced that it has acquired Cubiks Group Ltd (Cubiks), an international assessment and executive development business headquartered in Guildford, UK, with offices in 13 countries across Europe and Asia Pacific. The acquisition consolidates PSI's position as the pre-eminent talent management provider and represents a considerable development in both the breadth of...&#nl&#nlSource: RealWire"
  ["description"]=>
  string(574) "London, UK –28 October – PSI Services (PSI), a global workforce solutions provider with over 70 years’ experience in assessment and talent management, today announced that it has acquired Cubiks Group Ltd (Cubiks), an international assessment and executive development business headquartered in Guildford, UK, with offices in 13 countries across Europe and Asia Pacific. The acquisition consolidates PSI's position as the pre-eminent talent management provider and represents a considerable development in both the breadth of...&#nl&#nlSource: RealWire"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "4"
  ["category"]=>
  string(1) "4"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "65"
  ["rss_id"]=>
  string(2) "65"
  [14]=>
  string(75) "http://www.realwire.com/releases/PSI-Services-PSI-acquires-Cubiks-Group-Ltd"
  ["blog_url"]=>
  string(75) "http://www.realwire.com/releases/PSI-Services-PSI-acquires-Cubiks-Group-Ltd"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-10-31 15:50:34"
  ["create_at"]=>
  string(19) "2019-10-31 15:50:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "5344"
  ["article_id"]=>
  string(4) "5344"
  [1]=>
  string(93) "HR SaaS firm e-days appoints former Fairsail CEO as board advisor to accelerate global growth"
  ["article_title"]=>
  string(93) "HR SaaS firm e-days appoints former Fairsail CEO as board advisor to accelerate global growth"
  [2]=>
  string(150) "Nottingham, London, UK. 22nd October 2019. e-days, the Nottingham-based global absence management platform, has appointed former Fairsail CEO Adam Hal"
  ["short_description"]=>
  string(150) "Nottingham, London, UK. 22nd October 2019. e-days, the Nottingham-based global absence management platform, has appointed former Fairsail CEO Adam Hal"
  [3]=>
  string(539) "Nottingham, London, UK. 22nd October 2019. e-days, the Nottingham-based global absence management platform, has appointed former Fairsail CEO Adam Hale as a strategic advisor to the board, following recent rapid business growth. Hale is advisor to the ScaleUp Group, chairman of employee experience company eloomi and non-executive director of Unit4. At Fairsail, he grew the multi-award-winning HR SaaS business from £1m to £10m revenue before sale to Sage for £115 million.e-days has a pure SaaS...&#nl&#nlSource: RealWire"
  ["description"]=>
  string(539) "Nottingham, London, UK. 22nd October 2019. e-days, the Nottingham-based global absence management platform, has appointed former Fairsail CEO Adam Hale as a strategic advisor to the board, following recent rapid business growth. Hale is advisor to the ScaleUp Group, chairman of employee experience company eloomi and non-executive director of Unit4. At Fairsail, he grew the multi-award-winning HR SaaS business from £1m to £10m revenue before sale to Sage for £115 million.e-days has a pure SaaS...&#nl&#nlSource: RealWire"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "4"
  ["category"]=>
  string(1) "4"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "65"
  ["rss_id"]=>
  string(2) "65"
  [14]=>
  string(98) "http://www.realwire.com/releases/HR-SaaS-firm-e-days-appoints-former-Fairsail-CEO-as-board-advisor"
  ["blog_url"]=>
  string(98) "http://www.realwire.com/releases/HR-SaaS-firm-e-days-appoints-former-Fairsail-CEO-as-board-advisor"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-10-31 15:50:34"
  ["create_at"]=>
  string(19) "2019-10-31 15:50:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "5345"
  ["article_id"]=>
  string(4) "5345"
  [1]=>
  string(72) "Transforming the Talent Experience at Cornerstone Convergence EMEA 2019 "
  ["article_title"]=>
  string(72) "Transforming the Talent Experience at Cornerstone Convergence EMEA 2019 "
  [2]=>
  string(150) "More than 30 Cornerstone clients will present over the two-day conference, including Henkel, Novartis, Schneider Electric and Volvo Group London ̵"
  ["short_description"]=>
  string(150) "More than 30 Cornerstone clients will present over the two-day conference, including Henkel, Novartis, Schneider Electric and Volvo Group London ̵"
  [3]=>
  string(559) "More than 30 Cornerstone clients will present over the two-day conference, including Henkel, Novartis, Schneider Electric and Volvo Group London – 22 October 2019 – Cornerstone OnDemand, Inc. (NASDAQ: CSOD), a global leader in cloud-based learning, talent management and emerging talent experience software, today announced that it will host its annual client conference, Cornerstone Convergence EMEA, from 12th to 13th November, 2019 at the new and exciting location of Tobacco Dock, London.This year’s event will...&#nl&#nlSource: RealWire"
  ["description"]=>
  string(559) "More than 30 Cornerstone clients will present over the two-day conference, including Henkel, Novartis, Schneider Electric and Volvo Group London – 22 October 2019 – Cornerstone OnDemand, Inc. (NASDAQ: CSOD), a global leader in cloud-based learning, talent management and emerging talent experience software, today announced that it will host its annual client conference, Cornerstone Convergence EMEA, from 12th to 13th November, 2019 at the new and exciting location of Tobacco Dock, London.This year’s event will...&#nl&#nlSource: RealWire"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "4"
  ["category"]=>
  string(1) "4"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "65"
  ["rss_id"]=>
  string(2) "65"
  [14]=>
  string(104) "http://www.realwire.com/releases/Transforming-the-Talent-Experience-at-Cornerstone-Convergence-EMEA-2019"
  ["blog_url"]=>
  string(104) "http://www.realwire.com/releases/Transforming-the-Talent-Experience-at-Cornerstone-Convergence-EMEA-2019"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-10-31 15:50:34"
  ["create_at"]=>
  string(19) "2019-10-31 15:50:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "5346"
  ["article_id"]=>
  string(4) "5346"
  [1]=>
  string(69) "Cornerstone to Present the Power of People Potential at UNLEASH Paris"
  ["article_title"]=>
  string(69) "Cornerstone to Present the Power of People Potential at UNLEASH Paris"
  [2]=>
  string(150) "Alongside Cornerstone executives, Cornerstone client Novartis will share how the company transformed its learning cultureLONDON – 03 October 201"
  ["short_description"]=>
  string(150) "Alongside Cornerstone executives, Cornerstone client Novartis will share how the company transformed its learning cultureLONDON – 03 October 201"
  [3]=>
  string(580) "Alongside Cornerstone executives, Cornerstone client Novartis will share how the company transformed its learning cultureLONDON – 03 October 2019 - Cornerstone OnDemand, Inc. (NASDAQ: CSOD), a global leader in cloud-based learning, talent management and emerging talent experience market, today announced the company’s participation at UNLEASH Paris from 22nd to 23rd October 2019 at the Paris Convention Centre.Delegates are invited to visit Cornerstone at Stand 301 to explore how organisations can futureproof their HR strategies, realise...&#nl&#nlSource: RealWire"
  ["description"]=>
  string(580) "Alongside Cornerstone executives, Cornerstone client Novartis will share how the company transformed its learning cultureLONDON – 03 October 2019 - Cornerstone OnDemand, Inc. (NASDAQ: CSOD), a global leader in cloud-based learning, talent management and emerging talent experience market, today announced the company’s participation at UNLEASH Paris from 22nd to 23rd October 2019 at the Paris Convention Centre.Delegates are invited to visit Cornerstone at Stand 301 to explore how organisations can futureproof their HR strategies, realise...&#nl&#nlSource: RealWire"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "4"
  ["category"]=>
  string(1) "4"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "65"
  ["rss_id"]=>
  string(2) "65"
  [14]=>
  string(102) "http://www.realwire.com/releases/Cornerstone-to-Present-the-Power-of-People-Potential-at-UNLEASH-Paris"
  ["blog_url"]=>
  string(102) "http://www.realwire.com/releases/Cornerstone-to-Present-the-Power-of-People-Potential-at-UNLEASH-Paris"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-10-31 15:50:34"
  ["create_at"]=>
  string(19) "2019-10-31 15:50:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "5530"
  ["article_id"]=>
  string(4) "5530"
  [1]=>
  string(77) "Sanofi’s Fluzone quadrivalent formulation gets FDA nod in older people"
  ["article_title"]=>
  string(77) "Sanofi’s Fluzone quadrivalent formulation gets FDA nod in older people"
  [2]=>
  string(150) "Fluzone High-Dose (Influenza Vaccine) was approved as a trivalent influenza vaccine by the US regulator in 2009, which covered the two influenza A str"
  ["short_description"]=>
  string(150) "Fluzone High-Dose (Influenza Vaccine) was approved as a trivalent influenza vaccine by the US regulator in 2009, which covered the two influenza A str"
  [3]=>
  string(560) "
Fluzone High-Dose (Influenza Vaccine) was approved as a trivalent influenza vaccine by the US regulator in 2009, which covered the two influenza A strains and one influenza B 
&#nl
The post Sanofi’s Fluzone quadrivalent formulation gets FDA nod in older people appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(560) "
Fluzone High-Dose (Influenza Vaccine) was approved as a trivalent influenza vaccine by the US regulator in 2009, which covered the two influenza A strains and one influenza B 
&#nl
The post Sanofi’s Fluzone quadrivalent formulation gets FDA nod in older people appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(89) "https://www.pharmaceutical-business-review.com/news/sanofis-fluzone-vaccine-quadrivalent/"
  ["blog_url"]=>
  string(89) "https://www.pharmaceutical-business-review.com/news/sanofis-fluzone-vaccine-quadrivalent/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-06 14:38:14"
  ["create_at"]=>
  string(19) "2019-11-06 14:38:14"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "5531"
  ["article_id"]=>
  string(4) "5531"
  [1]=>
  string(86) "Boehringer Ingelheim and Lilly modernise alliance to focus full expertise on Jardiance"
  ["article_title"]=>
  string(86) "Boehringer Ingelheim and Lilly modernise alliance to focus full expertise on Jardiance"
  [2]=>
  string(150) "Trajenta (linagliptin) and Basaglar (insulin glargine) continue to be part of the Alliance, with primary responsibility for development and commercial"
  ["short_description"]=>
  string(150) "Trajenta (linagliptin) and Basaglar (insulin glargine) continue to be part of the Alliance, with primary responsibility for development and commercial"
  [3]=>
  string(658) "
Trajenta (linagliptin) and Basaglar (insulin glargine) continue to be part of the Alliance, with primary responsibility for development and commercialisation led by the innovator company. Boehringer Ingelheim will 
&#nl
The post Boehringer Ingelheim and Lilly modernise alliance to focus full expertise on Jardiance appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(658) "
Trajenta (linagliptin) and Basaglar (insulin glargine) continue to be part of the Alliance, with primary responsibility for development and commercialisation led by the innovator company. Boehringer Ingelheim will 
&#nl
The post Boehringer Ingelheim and Lilly modernise alliance to focus full expertise on Jardiance appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(139) "https://www.pharmaceutical-business-review.com/news/boehringer-ingelheim-and-lilly-modernise-alliance-to-focus-full-expertise-on-jardiance/"
  ["blog_url"]=>
  string(139) "https://www.pharmaceutical-business-review.com/news/boehringer-ingelheim-and-lilly-modernise-alliance-to-focus-full-expertise-on-jardiance/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-06 14:38:14"
  ["create_at"]=>
  string(19) "2019-11-06 14:38:14"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "5532"
  ["article_id"]=>
  string(4) "5532"
  [1]=>
  string(83) "Samsung Biologics and Ichnos Sciences announce agreement for manufacture of ISB 830"
  ["article_title"]=>
  string(83) "Samsung Biologics and Ichnos Sciences announce agreement for manufacture of ISB 830"
  [2]=>
  string(150) "Based on an entirely new mechanism of action, ISB 830 has the potential to treat a range of autoimmune diseases beyond atopic dermatitis. Enrollment i"
  ["short_description"]=>
  string(150) "Based on an entirely new mechanism of action, ISB 830 has the potential to treat a range of autoimmune diseases beyond atopic dermatitis. Enrollment i"
  [3]=>
  string(609) "
Based on an entirely new mechanism of action, ISB 830 has the potential to treat a range of autoimmune diseases beyond atopic dermatitis. Enrollment in a large randomized 
&#nl
The post Samsung Biologics and Ichnos Sciences announce agreement for manufacture of ISB 830 appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(609) "
Based on an entirely new mechanism of action, ISB 830 has the potential to treat a range of autoimmune diseases beyond atopic dermatitis. Enrollment in a large randomized 
&#nl
The post Samsung Biologics and Ichnos Sciences announce agreement for manufacture of ISB 830 appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(136) "https://www.pharmaceutical-business-review.com/news/samsung-biologics-and-ichnos-sciences-announce-agreement-for-manufacture-of-isb-830/"
  ["blog_url"]=>
  string(136) "https://www.pharmaceutical-business-review.com/news/samsung-biologics-and-ichnos-sciences-announce-agreement-for-manufacture-of-isb-830/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-06 14:38:14"
  ["create_at"]=>
  string(19) "2019-11-06 14:38:14"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}